Optimised subcutaneous therapeutic agents
US11351112B2 · kind B2 · utility
0Cited by
12References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 30, 2017 |
| Grant date | Jun 7, 2022 |
| Priority date | — |
| Expiry date | Aug 30, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.